• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression home Treatment for depression (longisland.com)

For a lot of people suffering from depression, traditional therapy and medication isn't effective. A customized treatment could be the solution.

Cue is a digital intervention platform that transforms passively acquired sensor data from smartphones into personalised micro-interventions designed to improve mental health. We analysed the best-fit personalized ML models for each subject using Shapley values to discover their predictors of feature and reveal distinct features that deterministically change mood over time.

Predictors of Mood

Depression is among the world's leading causes of mental illness.1 However, only about half of those who have the condition receive treatment1. In order to improve outcomes, doctors must be able to identify and treat patients with the highest chance of responding to particular treatments.

The ability to tailor depression treatments is one way to do this. Using mobile phone sensors as well as an artificial intelligence voice assistant, and other digital tools researchers at the University of Illinois Chicago (UIC) are working on new ways to predict which patients will benefit from the treatments they receive. With two grants totaling more than $10 million, they will employ these technologies to identify biological and behavioral predictors of the response to antidepressant medication and psychotherapy.

The majority of research conducted to so far has focused on clinical and sociodemographic characteristics. These include demographics such as gender, age and education, as well as clinical characteristics like severity of symptom and comorbidities as well as biological markers.

A few studies have utilized longitudinal data to determine mood among individuals. A few studies also take into consideration the fact that mood can vary significantly between individuals. It is therefore important to devise methods that allow for the identification and quantification of individual differences between mood predictors, treatment effects, etc.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team is able to develop algorithms to detect patterns of behaviour and emotions that are unique to each individual.

The team also developed a machine learning algorithm to model dynamic predictors for the mood of each person's postnatal depression treatment. The algorithm combines these individual variations into a distinct "digital phenotype" for each participant.

This digital phenotype has been correlated with CAT DI scores, a psychometrically validated symptom severity scale. The correlation was weak however (Pearson r = 0,08; P-value adjusted for BH = 3.55 10 03) and varied greatly between individuals.

Predictors of symptoms

depression treatment resistant is among the most prevalent causes of disability1, but it is often underdiagnosed and undertreated2. In addition the absence of effective interventions and stigmatization associated with depressive disorders prevent many individuals from seeking help.

To aid in the development of a personalized treatment, it is crucial to identify predictors of symptoms. The current prediction methods rely heavily on clinical interviews, which are unreliable and only identify a handful of characteristics that are associated with depression treatment without medication.

Machine learning can improve the accuracy of the diagnosis and treatment of depression and treatment by combining continuous digital behavior phenotypes gathered from smartphones along with a verified mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). These digital phenotypes allow continuous, high-resolution measurements. They also capture a wide range of distinctive behaviors and activity patterns that are difficult to document using interviews.

The study comprised University of California Los Angeles students with mild to severe depression symptoms who were enrolled in the Screening and Treatment for Anxiety and depression treatment plan cbt program29 developed as part of the UCLA Depression Grand Challenge. Participants were directed to online support or in-person clinical care depending on their depression severity. Patients with a CAT DI score of 35 65 were assigned to online support with the help of a peer coach. those who scored 75 patients were referred to in-person clinical care for psychotherapy.

At baseline, participants provided a series of questions about their personal demographics and psychosocial features. The questions included age, sex, and education and marital status, financial status, whether they were divorced or not, current suicidal thoughts, intentions or attempts, as well as the frequency with which they consumed alcohol. The CAT-DI was used to rate the severity of depression symptoms on a scale from 0-100. CAT-DI assessments were conducted every other week for participants that received online support, and every week for those who received in-person support.

Predictors of Treatment Response

Research is focusing on personalization of depression treatment. Many studies are aimed at identifying predictors, which will aid clinicians in identifying the most effective drugs to treat each individual. Pharmacogenetics in particular identifies genetic variations that determine how the body's metabolism reacts to drugs. This allows doctors to select the medications that are most likely to work best for each patient, while minimizing the time and effort required in trials and errors, while eliminating any side effects that could otherwise slow advancement.

Another promising approach is building prediction models using multiple data sources, combining clinical information and neural imaging data. These models can be used to identify which variables are the most predictive of a specific outcome, like whether a medication will improve symptoms or mood. These models can be used to predict the response of a patient to treatment, allowing doctors to maximize the effectiveness.

A new generation employs machine learning techniques such as algorithms for classification and supervised learning such as regularized logistic regression, and tree-based methods to combine the effects of multiple variables and improve predictive accuracy. These models have proven to be effective in forecasting treatment outcomes, such as the response to antidepressants. These methods are becoming more popular in psychiatry, and are likely to become the standard of future treatment.

Research into depression's underlying mechanisms continues, as do ML-based predictive models. Recent research suggests that the disorder is connected with neural dysfunctions that affect specific circuits. This theory suggests that the treatment for depression will be individualized built around targeted therapies that target these neural circuits to restore normal functioning.

One method of doing this is to use internet-based interventions that offer a more individualized and personalized experience for patients. One study found that a web-based program was more effective than standard treatment in reducing symptoms and ensuring the best quality of life for those with MDD. In addition, a controlled randomized study of a customized approach to treating depression showed sustained improvement and reduced side effects in a significant proportion of participants.

Predictors of side effects

A major issue in personalizing depression treatment involves identifying and predicting the antidepressant medications that will have very little or no side effects. Many patients are prescribed a variety of medications before finding a medication that is both effective and well-tolerated. Pharmacogenetics offers a fresh and exciting method to choose antidepressant drugs that are more efficient and targeted.

Many predictors can be used to determine which antidepressant to prescribe, such as gene variants, patient phenotypes (e.g. gender, sex or ethnicity) and comorbidities. To determine the most reliable and valid predictors of a specific treatment, randomized controlled trials with larger sample sizes will be required. This is because the detection of interactions or moderators can be a lot more difficult in trials that focus on a single instance of treatment per person, rather than multiple episodes of treatment over a period of time.

Additionally the estimation of a patient's response to a specific medication is likely to require information on comorbidities and symptom profiles, in addition to the patient's prior subjective experience of its tolerability and effectiveness. Currently, only a few easily measurable sociodemographic variables as well as clinical variables appear to be reliable in predicting the response to MDD. These include age, gender and race/ethnicity, SES, BMI and the presence of alexithymia.

The application of pharmacogenetics to depression treatment is still in its early stages, and many challenges remain. First, it is important to have a clear understanding and definition of the genetic mechanisms that cause depression, and an understanding of an accurate indicator of the response to treatment. In addition, ethical issues, such as privacy and the ethical use of personal genetic information, should be considered with care. Pharmacogenetics can, in the long run reduce stigma associated with treatments for mental illness and improve the outcomes of treatment. But, like all approaches to psychiatry, careful consideration and planning is essential. At present, the most effective course of action is to offer patients various effective medications for depression and encourage them to talk with their physicians about their concerns and experiences.